Albireo's A3309 meets constipation endpoint

Albireo (Gothenburg, Sweden) said 10 and 15 mg once-daily oral A3309 for eight weeks met the primary endpoint in a Phase IIb trial to treat chronic idiopathic constipation. A3309 significantly increas...